On Thursday, April 14, 2022, Duke Cancer Institute clinical providers, researchers, staff, and leadership came together to celebrate the 50th anniversary of the Duke Comprehensive Cancer Center (now called Duke Cancer Institute).

As the DCI 50^th kickoff celebration was gearing up on the grassy circle in front of Duke Cancer Center building in Durham, a few patients stopped by the adjacent Seese-Thornton Garden of Tranquility for some respite.

A breast cancer patient of Susan Dent, MD, braced for a long day of chemotherapy infusions. A man with stage 3 melanoma, being treated by Brent Hanks, MD, chatted in the shade of a tree with his wife ahead of his next appointment. A woman on her way to the Duke South clinics, meanwhile, shared her worries over her brother’s recent esophageal cancer diagnosis, their strong family history of cancer, and the importance of keeping up with her mammograms.

Joe Moore, MD — who hung up his DCI lab coat in 2019 after a 44-year Hematology /Oncology career — was admiring the newly-installed Sound of Hope bell (a gift of the J. Gordon Wright family in honor of Nancy Wright, a pancreatic cancer survivor) before Jana Wagenseller, RN, escorted him across the grass to a front-row seat, stage right. (Moore had begun his medical career at Duke in 1975 as a fellow and Wagenseller had begun her nursing career at Duke in 1976 and served in multiple leadership roles before retiring in 2004).

The Duke University Marching Band made a jubilant entrance onto the green and briefly performed in front of a big-screen slideshow showcasing moments in DCI history before the official program began.

Executive director of DCI Michael B. Kastan, MD, PhD, began by thanking the “spirited” band and welcoming the more than 500 attendees. He asked for a round of applause “for all of the talented and dedicated staff, physicians and researchers and residents who give our patients hope every single day,” then turned his focus to DCI’s thousands of patients, past and present.

“Though we’re celebrating many successes over the last 50 years, not every story is a success,” he said. “We’ve lost a lot of patients, family, and friends over the years. And I’d like to take a moment of silence so we can think about them as we move forward.”

In addition to celebrating the 50th anniversary of Duke’s recognition as a National Cancer Institute-designated Comprehensive Cancer Center, Kastan also recognized the ten-year anniversary of the stand-alone Duke Cancer Center building and the creation of the Duke Cancer Institute.

For this, he commended the leadership and direction of Victor Dzau, MD (a Duke cardiologist and pathologist who served as chancellor of Health Affairs from 2004 to 2014), Dean Emerita of the Duke University School of Medicine Nancy Andrews, MD, PhD (Pediatrics and Pharmacology & Cancer Biology), and Bill Fulkerson, Jr., MD, MBA, who served for the past 10 years as executive vice president of DUHS before stepping down in December.

“With his unwavering commitment to the DCI’s growth and care of our patients, I am proud to recognize Dr. Fulkerson among our attendees here today,” said Kastan, giving a nod to the pulmonologist who began his clinical career at Duke nearly 40 years ago. “Today we continue in our commitment to making innovative discoveries developing new ways to prevent, diagnose, and treat cancer and deliver those therapies in a patient-centric and family-centric way.”

“Everybody in academic medicine knows about the DCI. It’s legendary,” said executive vice president of DUHS Craig Albanese, MD, who took the podium after Kastan. “There’s so much to be proud of in the last 50 years — the research, the training, the breakthrough treatments, and the exceptional cancer support services.”

Albanese also singled out the DCI’s thriving community partnerships.

“Our strategic work with community organizations is critical. It’s part of our mission. It’s fundamental to the fabric of the organization. We should be proud of that,” he said. “The DCI’s Community Outreach, Engagement, and Equity program is a national leader in addressing inequities in prevention and treatment through health education, cancer screening for early detection, and ensuring that people have access to primary care. And as a health system, our focus is on health equity, not just because it’s the right thing to do, but because it’s really critical for the health of our community. And in fact, it’s critical for the health of our nation. So, let’s all extend our gratitude towards those who do this profound and meaningful work.”

“What do I see for the future? It’s going to be a different future, a future based largely on automation, digital health, genomic studies, personalized care,” predicted Albanese, a seasoned healthcare executive and distinguished academic pediatric surgeon. “But in the end, it is compassion, empathy, patient experience, access, and community advancement that’s going to continue to make us who we are and make us unique…Certainly, if the last 50 years are any indication, I can’t wait to see what the next 50 years will bring.”

Mary Klotman, MD, dean of the Duke University School of Medicine, rounded out the speakers’ program with a deeper dive back in time. She traced the history of cancer care and research back to 1937 when one of the first brain tumor centers in the country was founded (Preston Robert Tisch Brain Tumor Center), and to 1947 when the first training program for medical students focused on clinical cancer care was established — all decades before the NCI designation.

And she noted key research milestones:

• 1950: Duke professor Joseph Beard, MD, received a grant from the American Cancer Society. Through that work, he and his team at Duke were one of the two groups to first report evidence of viruses in association with human leukemia.
   
• 1964: Bill Joklik, D.Phil (Oxford) was the first to examine the mechanism of action of interferon — the first cytokine to be recognized — in molecular terms.
   
• 1994: Duke scientists helped discover the BRCA1 and BRCA2 genes responsible for many inherited forms of breast and ovarian cancers.
   
• 2018: A genetically modified poliovirus therapy developed at DCI showed significantly improved long-term survival for patients with recurrent glioblastoma

Klotman also highlighted the construction, in 1994, of two new buildings dedicated to research (the LSRC and the MSRB), the creation of the DCI in 2012, and the more recent founding of the pioneering Duke Center for Brain and Spine Metastasis that received critical support from Chancellor Eugene Washington’s Translating Duke Health Initiative.

“Whether you’re a researcher, physician, provider, patient, or trainee, I truly believe there is no better place to fight cancer than at Duke,” Klotman said. “Thank you all for what you do every day.”

“In March and April 2019, I was diagnosed with late-stage lymphoma. I want you to know that my panic and anxiety lasted about two minutes. And that was in prayer. And my God let me know that I was healed for a greater cause. But then, in the next five minutes, I was calling the Cancer Center.

Over the next few weeks of tests and discoveries and figuring out the best treatment, for me as a coach (there were) three things — physical, mental, and emotional. The cancer for me was the physical (part). I had to immediately treat the emotional. As I walked my way through these halls, all the tests — whether it was the lab or the radiologist, this test and that test — and while I had confidence in the physical science that Duke has here, I was reassured that my confidence would be reinforced every step of the way.

I was asked who in the hospital made the biggest difference, but with cancer, it’s every kind word, every word of understanding, every word of compassion. Every single individual I met from day one to nine months later after inpatient chemo reassured me. I was confident about the facts, but the emotional and the mental was nurtured every single step of the way. And it changed my life. My life has been dedicated to helping young people reach their goals. As I walk these halls my purpose has changed, and that’s to help all families and all communities endure an incredible journey.

So, thanks to all! I don’t know all the names. The leader was Dr. (Jie) Wang, but there was a tremendous team that made it all happen. So, I wanted to take a second to say thank you for the nurturing, thank you.”

“I wanted to say thank you to all of you for your speeches. That was wonderful. So great to hear that information. My name is Elle Charnisky. I was diagnosed with stage four metastatic colorectal cancer in April 2016 with metastasis to my liver and both lungs at age 36. My husband Mike, you’re my rock. And we celebrate our 15th wedding anniversary this fall. And our kids Molly — who is here with me today — and Grant were one and four at the time. I endured the very harsh standard first and second line chemo at Siteman in St. Louis, for a little over a year, until just as it seemed we were running out of options, my second opinion doc, Dr. Nancy Kemeny at Memorial Sloan Kettering Cancer Center in New York, turned our worlds upside down and referred me here to the Duke Cancer Center.

When we sat down in the office of Dr. John Strickler, who is truly one in a million, we had a sense that our lives were never going to be the same. I think Dr. Strickler was trying to give us that sense and he was not wrong. He was the principal investigator of a new up and coming targeted therapy clinical trial for colorectal cancer patients with a strong HER 2 amplification,  known as the Mountaineer trial. That trial, by the grace of God gave me my life back. That very first treatment I remember feeling like I wasn’t even on treatment at all. After my first scans since having started the trial, I remember Dr. S as I like to call him bringing up the impressive results and saying, ‘And I don’t think we’re done taking a sledgehammer to it yet.’ And he was right.

It kept the disease in full remission for nearly three years. Being a metastatic cancer patient, I had never been eligible for surgery up until that point, but the Mountaineer trial got me to where I was. My incredible team of doctors and nurses here at the Duke Cancer Center, doctors Manisha Palta, Julie Thacker, and Sabino Zani to name a few, reevaluated my case and deemed me eligible to have the lifesaving surgeries I needed.

I was even able to continue on with the Mountaineer trial for some time after those surgeries and had continued success on the trial until April of last year. And to this day, amazingly, I’m on a very similar targeted therapy regimen with no adverse side effects and full quality of life.

My time here at the Duke Cancer Center has been second to none, from the peaceful serene atmosphere — my favorite is when they play Ave Maria on the grand piano at the basement level — to the incredible nursing staff and counselors. I have to give a shout-out to Evan Dropkin, Leighanne Hartman, and Tracy Berger, and the research team of doctors. I truly cannot imagine it not being a part of my life. So, I would love to invite my team of care providers to come join me on the stage. Thank you so much!”

“I’m grateful, humbled, and honored to have been asked to participate. First of all, I just want to say that I got here at Duke by divine intervention. What I mean by this is  (that) I had an initial opinion back in Augusta, Georgia. My name is John Sanders. I got so excited, I didn’t tell you my name, but that’s ok.

So, I went to the initial consultation in Augusta. It wasn’t what I needed, didn’t feel it. So, I went home and I began to pray. ‘Lord, where should I go? What should I do?’ And God spoke to me and said, ‘Come to Duke.’ So I was led here by divine intervention. And I’m happy that I did.

When I came here for the initial consultation, my family and I met with Dr. Kevin Naresh Shah, and I asked him, ‘How you gonna operate on me with them little hands?’ And he said, ‘I’m the damn best you got.’ Getting diagnosed with pancreatic cancer, of course, was a death sentence. But he told me he could do the laparoscopic Whipple and we did that for 12 hours and then I had to do massive chemotherapy.

That’s when I met Dr. John Howard Strickler. He had just gotten back from France from a pancreatic cancer forum. He said, ‘This (inaudible) is the greatest and you are the first patient,’ but he reassured me that I’ll be okay. He said, ‘Your attitude is great. Your faith is great. Your fitness is good. And we will be with you every step of the way.’ So, I had hope and encouragement. And don’t forget what he told me. Dr. Strickler told me he was gonna throw the papa-bear treatment at me. So we went through that for about a year. Then after that, I came back to Duke for radiation and oral chemo under Dr. Manisha Palta. So, she and her team were also great.

It has been a great, wonderful, remarkable experience for me at Duke. I tell everyone, everywhere I go, ‘If you want to live, you need to come to Duke.’ Let me say that again. ‘If you want to live, you need to come to Duke. It will never give up on you.’ And my hope, my faith, and my resilience has never been stronger.

I have a good friend now who has retinitis pigmentosa. I told him to come to Duke and now he’s here in the research program for retinitis pigmentosa. Every chance I get, I’m telling my story, because I’m a miracle to survive pancreatic cancer.

But I also tell the story of Duke being my support system. Everyone, I told everyone, that from the time I park my car until I get to the labs, to the CT scan, this has been a wonderful, rewarding experience for me, and I hope to finish this journey with Duke that I started. It’s been remarkable. It’s awesome. And this just this gives me resilience and the tenacity to want to fight and want to win. Because when I come back to Duke, I want them to see that we are doing well because of Duke and you all. That’s why I’m here. Thank you.”